華森製藥(002907.SZ):藥品生產許可證變更
格隆匯 3 月 17日丨華森製藥(002907.SZ)公佈,公司於近日收到重慶市藥品監督管理局頒發的《藥品生產許可證》(許可證編號:渝20150018),此次主要涉生產範圍的變更。變更內容如下:
(一)質量負責人:由Chen Jin變更為鄧林,質量授權人:由鄧林變更為王茜。
(二)重慶市榮昌區昌州街道板橋路143號:凍乾粉針劑(車間:502車間;生產線:凍乾粉針劑生產線)、粉針劑(車間:502車間;生產線:粉針劑生產線)、散劑(車間:503車間;生產線:散劑生產線)、中藥前處理及提取(車間:505車間;生產線:中藥前處理及提取生產線);重慶市榮昌區工業園區:原料藥(鋁碳酸鎂)(車間:三車間;生產線:鋁碳酸鎂二期合成生產線)。
(三)增加委託方和委託品種信息:委託方是佑華醫藥科技有限公司,生產地址是重慶市榮昌區昌州街道板橋路143號,委託產品為恩替卡韋片,孟魯司特鈉顆粒,合同有效期至2025年11月9日。
此次《藥品生產許可證》變更有利於豐富公司產品結構,更好滿足市場需求。短期內對公司業績無重大影響,敬請投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.